Stay up to date on the latest oncology and nursing conferences.
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLCAugust 5th 2022
Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.
Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast CancerAugust 1st 2022
Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST TumorsJuly 27th 2022
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Kahl Discusses the Future of Maintenance Therapy in Mantel Cell LymphomaJuly 24th 2022
An expert with the Washington University School of Medicine in St Louis outlines the benefit of rituximab, and other maintenance therapies, for patients with mantel cell lymphoma who are in remission.
Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCLJuly 23rd 2022
Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.
Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCLJuly 22nd 2022
A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Ixazomib/Lenalidomide/Dexamethasone Shows Consistent Outcomes in 3 Real-World Analyses of Use for Patients with R/R Multiple MyelomaJuly 21st 2022
A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.
Zanubrutinib Significantly Improves PFS in Treatment-Naïve CLL/SLL Across Various High-Risk SubsetsJuly 21st 2022
Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.
Oncology APPs, Research Nurses Are Uniquely Poised to Tackle irAE Management in Follicular LymphomaJuly 20th 2022
Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.
Extended Follow-Up Shows Durable Outcomes, No New Safety Signals With Brexucabtagene Autoleucel in R/R B-ALLJuly 19th 2022
Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.
Gretchen McNally Speaks to the Role of Oncology Nurses in the Opioid EpidemicJuly 18th 2022
Gretchen McNally PhD, ANP-BC, AOCN, spotlights the value that naloxone training for oncology nurses and providers could have for patients who are at a high-risk of overdose.
Frontline Ribociclib-Related Quality of Life Favorable to Abemaciclib in HR+/HER2- Advanced Breast CancerJuly 15th 2022
Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced MelanomaJuly 13th 2022
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Zanubrutinib Associated With Better Quality of Life Vs Bendamustine/Rituximab in CLL/SLLJuly 3rd 2022
Investigators have identified that zanubrutinib may improve the subpar health-related quality of life for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.